Fig. 7.

Effects of palbociclib on disease progression in the Su/Hox rat model of pulmonary arterial hypertension. a Scheme of animal treatments. Echocardiograms were recorded at baseline, 21 days after Su5416 administration at the beginning of hypoxia exposure and again on day 35 after a 14-day period of treatment with 75 mg/kg body weight palbociclib (or placebo) daily by gavage under re-exposure to normoxic conditions. b–l On day 35, hemodynamics and cardiac function were assessed in vivo 14 days after treatment with palbociclib (Su/Hox + Palbo, n = 7) (under initial hypoxia exposure). Similarly, normoxic rats (n = 8) and animals injected with Su5416 and placebo (under initial hypoxia exposure) (Su/Hox, n = 8) were used as control groups. Data are presented as mean ± SEM and statistical analysis was performed using one-way ANOVA with Newman–Keuls post-hoc test for multiple comparisons; *p < 0.05, **p < 0.01, ***p < 0.001 for Su/Hox + Palbo versus Su/Hox; ^§ < 0.05, ^§§p < 0.01, ^§§§p < 0.001 for Su/Hox + Palbo versus Nox; ^# < 0.05, ^##p < 0.01, ^###p < 0.001 for Nox versus Su/Hox. Source data are provided as a Source Data file